Authors:
BONNEFOI H
DIEBOLDBERGER S
HAMILTON A
VANDEVIJVER M
MACGROGAN G
SHEPHERD L
AMARAL N
RAOUST I
DRIJKONINGEN M
THERASSE P
PICCART M
Citation: H. Bonnefoi et al., A STUDY OF MOLECULAR MARKERS WITH POTENTIAL PROGNOSTIC AND PREDICTIVEVALUE (C-ERBB-2, P53, CYCLIN D1, MIB1, ER AND PGR) IN LOCALLY ADVANCED BREAST-CANCER TREATED WITH NEOADJUVANT DOSE-INTENSIVE CHEMOTHERAPY IN AN EORTC-NCIC-SAKK RANDOMIZED PHASE-III STUDY, European journal of cancer, 34, 1998, pp. 133-133
Citation: A. Hugli et al., CONTINUOUS INFUSIONAL 5-FLUOROURACIL (F) WITH EPIRUBICIN (E) AND CARBOPLATIN (ECARBOF) REGIMEN IN LOCALLY ADVANCED (LABC) OR METASTATIC BREAST-CANCER (MBC), Annals of oncology, 9, 1998, pp. 89-89
Authors:
HOSLI P
BONNEFOI H
MIRIMANOFF RO
MERMILLOD B
ALBERTO P
Citation: P. Hosli et al., EFFECT OF LOW-DOSE CHEST IRRADIATION BEFORE CHEMOTHERAPY ON THE RATE OF LOCAL FAILURE IN SMALL-CELL LUNG-CANCER, International journal of radiation oncology, biology, physics, 41(2), 1998, pp. 287-289
Authors:
PARMAR MKB
TORRI V
BONAVENTURA A
BONAZZI C
COLOMBO N
DELALOYE JF
MARSONI S
MANGIONI C
SANDERCOCK J
SESSA C
WILLIAMS C
TINAZZI A
FLANN M
GEISER K
SCORPIGLIONE N
STEWART JF
CHAVES J
PALMEIRO E
CURTAIN A
MCCORMACK T
GENNATAS C
MARRAS F
OPPO TG
BALESTRINO M
MALZONI C
MALZONI M
BELLI M
GEMINIANI ML
CRESTANI G
MONACO A
VAVALA V
PIATTO E
BARATTINI G
FORNARA PG
CHETRI MC
SANTEUFEMIA G
ARTIOLI F
CARONE D
FANIZZA G
TRENTADUE R
PRIOLO D
SCOLLO P
NIGRO SC
PETRINA M
MASTRANTONIO P
SPANNA GD
ZAGNI R
BELLONI C
COLLEONI R
REDAELLI L
CAVAGNINI A
DICOSTANZO G
PERRONI D
ARIENTI S
ORFANOTTI G
CANTONI FM
SECLI R
BIANCHI A
MARTINELLO R
MOLLICA G
MAIZZI D
PICCHIARELLI ME
FIORINI G
BORSANI M
COLOMBO E
GARSIA S
MELGRATI L
PAGGI G
BRUNENGHI GM
CASINI M
ISA L
ALGERI R
PROZIO G
BELFIORE G
ANGELINI F
DAPRILE M
MORESCHI M
MAURI ML
NATALE N
SENZANI FM
PAVANATO G
POGGI G
GARUTI G
LUERTI M
CRUCIANI G
PAGANO F
BACCOLO M
PODDI ER
BOCCIOLONE L
SABELLI MA
MAGGI R
RESTELLI C
DANTONA A
LOCATELLI MC
PESSI A
RAINA A
CHIARI S
GABRIELE A
PITTELLI MR
IACOBELLI P
DOGLIOTTI L
GORZEGNO G
MUSSO P
VEGNA G
COCO G
ALLETTI DG
PICCIOTTO F
LUCCHESE V
EPIS A
DIPALUMBO VS
DRUDI G
RAVAIOLI A
ZAMPELLA D
MORANDI MG
GORGA G
ZUCCHELLI C
CARIELLO S
GALLETTO L
SUSSIO M
MASSACESI L
MASSACESI M
CARLI A
TUCCI E
TAJANI E
CORRADO G
BUMMA S
DURANDO A
MASSOBRIO M
SBERVEGLIERI M
BIASIO M
GUERCIO E
JURA R
DANESE S
WIERDIS T
FARNELLI C
TARANTINO G
GRASSI R
REPETTI F
ROCCHI B
GRAMPA M
ERCOLI A
GRISO C
SIGNORI E
ZANINI L
PRESTI M
KLIMEK M
URBANSKI K
BISWAS A
VIEGAS O
KOCHLI O
DREHER E
FEY M
BECK G
LUDIN J
BONNEFOI H
KRAUER F
BAUER J
DELMORE G
FURRER C
LORENZ U
THURLIMANN B
LORENZ U
BRONZ L
SANNA P
WYSS D
GOLDHIRSCH A
GYR T
LEIDI L
PASTORELLI G
PAGANI O
REY P
HAILER U
BENZ J
KAYE SB
REED NS
SYMONDS RP
ATKINSON RJ
AXFORD AT
RUSTIN G
SECKL MJ
GREEN JA
SCOTT IV
GUTHRIE D
HARPER PG
CALMAN F
DOBBS HJ
WEIR P
CASSONI A
LEDERMAN JA
SOUHAMI RL
BOZZINO J
ADAB F
REDMAN CWE
SCOBLE JE
PATERSON M
DANIEL F
COWLEY N
WILLIAMS CJ
SPOONER D
HONG A
MCILLMURRAY M
HENDYIBBS P
HALL V
IVESON TJ
WHITEHOUSE JMA
GARRY R
LAMONT A
ROBINSON A
TRASK CW
CLUBB AW
MURRELL D
NEWMAN G
WILKINS M
GOLDTHORP WO
ROBERTS JK
RADSTONE DJ
WHIPP MJ
LEDERMANN JA
PATER J
BUYSE M
OMURA G
Citation: Mkb. Parmar et al., ICON2 - RANDOMIZED TRIAL OF SINGLE-AGENT CARBOPLATIN AGAINST 3-DRUG COMBINATION OF CAP (CYCLOPHOSPHAMIDE, DOXORUBICIN, AND CISPLATIN) IN WOMEN WITH OVARIAN-CANCER, Lancet, 352(9140), 1998, pp. 1571-1576
Authors:
HURNY C
VANWEGBERG B
BACCHI M
BERNHARD J
THURLIMANN B
REAL O
PEREY L
BONNEFOI H
COATES A
Citation: C. Hurny et al., SUBJECTIVE HEALTH ESTIMATIONS (SHE) IN PATIENTS WITH ADVANCED BREAST-CANCER - AN ADAPTED UTILITY CONCEPT FOR CLINICAL-TRIALS, British Journal of Cancer, 77(6), 1998, pp. 985-991
Authors:
THURLIMANN B
CASTIGLIONE M
HSUSCHMITZ SF
CAVALLI F
BONNEFOI H
FEY MF
MORANT R
LOHNERT T
GOLDHIRSCH A
Citation: B. Thurlimann et al., FORMESTANE VERSUS MEGESTROL-ACETATE IN POSTMENOPAUSAL BREAST-CANCER PATIENTS AFTER FAILURE OF TAMOXIFEN - A PHASE-III PROSPECTIVE RANDOMIZED CROSS-OVER TRIAL OF 2ND-LINE HORMONAL TREATMENT (SAKK-20 90)/, European journal of cancer, 33(7), 1997, pp. 1017-1024
Citation: H. Bonnefoi et Ie. Smith, HOW SHOULD CANCER PRESENTING AS A MALIGNANT PLEURAL EFFUSION BE MANAGED, British Journal of Cancer, 74(5), 1996, pp. 832-835
Authors:
BONNEFOI H
SMITH IE
OBRIEN MER
SEYMOUR MT
POWLES TJ
ALLUM WH
EBBS S
BAUM M
Citation: H. Bonnefoi et al., PHASE-II STUDY OF CONTINUOUS INFUSIONAL 5-FLUOROURACIL WITH EPIRUBICIN AND CARBOPLATIN (INSTEAD OF CISPLATIN) IN PATIENTS WITH METASTATIC LOCALLY ADVANCED BREAST-CANCER (INFUSIONAL ECARBOF) - A VERY ACTIVE ANDWELL-TOLERATED OUTPATIENT REGIMEN, British Journal of Cancer, 73(3), 1996, pp. 391-396
Authors:
OBRIEN MER
BONNEFOI H
SEYMOUR M
WALSH G
RAMAGE F
SMITH IE
Citation: Mer. Obrien et al., INFUSIONAL 5-FLUOROURACIL (F) WITH EPIRUBICIN (E) AND CARBOPLATIN (ECARBOF) IN ADVANCED METASTATIC BREAST-CANCER (ABC) - CAN CARBO REPLACE CISPLATIN (C), European journal of cancer, 31A, 1995, pp. 367-367
Authors:
BONNEFOI H
ZULIAN GB
MIRIMANOFF RO
MERMILLOD B
ALBERTO P
Citation: H. Bonnefoi et al., PRIMING LOW-DOSE CHEST RADIOTHERAPY FOLLOWED BY CHEMOTHERAPY FOR LIMITED SMALL-CELL LUNG-CANCER, Annals of oncology, 5(8), 1994, pp. 771-772